Zogenix Stock Company Profile
Information
5858 Horton Street
Emeryville CA 94608
510-550-8300
www.zogenix.com
Description
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The companys lead product candidate is the ZX008, a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome. It also develops Relday, an injectable formulation of risperidone that is in Phase III clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. In addition, Zogenix, Inc. provides contract manufacturing services. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.